These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15650421)

  • 21. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
    Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal aminotransferases levels.
    Pace FH; Ferreira LE; Silva AE; Ferraz ML
    Rev Soc Bras Med Trop; 2012; 45(4):444-7. PubMed ID: 22930041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
    Suárez-Zarracina T; Valle-Garay E; Collazos J; Montes AH; Cárcaba V; Carton JA; Asensi V
    J Viral Hepat; 2012 Oct; 19(10):685-93. PubMed ID: 22967099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Berenguer J; Bellón JM; Miralles P; Alvarez E; Castillo I; Cosín J; López JC; Sánchez Conde M; Padilla B; Resino S
    Clin Infect Dis; 2008 Jan; 46(1):137-43. PubMed ID: 18171229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients.
    Monto A; Kakar S; Dove LM; Bostrom A; Miller EL; Wright TL
    Am J Gastroenterol; 2006 Jul; 101(7):1509-15. PubMed ID: 16863554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological status does not influence hepatitis c virus or liver fibrosis in HIV-hepatitis C virus-coinfected patients.
    Collazos J; Cartón JA; Asensi V
    AIDS Res Hum Retroviruses; 2011 Apr; 27(4):383-9. PubMed ID: 20977357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of liver fibrosis in monoinfected patients by hepatitis C virus and coinfected by HCV and human immunodeficiency virus.
    Tovo CV; Becker SC; Almeida PR; Galperim B; Chaves S
    Arq Gastroenterol; 2013; 50(1):19-22. PubMed ID: 23657302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
    Pineda JA; García-García JA; Aguilar-Guisado M; Ríos-Villegas MJ; Ruiz-Morales J; Rivero A; del Valle J; Luque R; Rodríguez-Baño J; González-Serrano M; Camacho A; Macías J; Grilo I; Gómez-Mateos JM;
    Hepatology; 2007 Sep; 46(3):622-30. PubMed ID: 17659577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.
    Bräu N; Salvatore M; Ríos-Bedoya CF; Fernández-Carbia A; Paronetto F; Rodríguez-Orengo JF; Rodríguez-Torres M
    J Hepatol; 2006 Jan; 44(1):47-55. PubMed ID: 16182404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver stiffness values in HIV-infected patients with isolated anti-hepatitis B core antibodies.
    Chakvetadze C; Bani-Sadr F; Lescure FX; Fontaine C; Le Pendeven C; Bonnard P; Mariot P; Soussan P; Pialoux G
    Med Mal Infect; 2013 Jun; 43(6):222-5. PubMed ID: 23597924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
    Pineda JA; Macías J
    J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients.
    Fernández-Montero JV; Barreiro P; de Mendoza C; Labarga P; Soriano V
    J Viral Hepat; 2016 Jan; 23(1):47-52. PubMed ID: 26390144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.
    Brunet L; Moodie EEM; Young J; Cox J; Hull M; Cooper C; Walmsley S; Martel-Laferrière V; Rachlis A; Klein MB; ; Cohen J; Conway B; Cooper C; Côté P; Cox J; Gill J; Haider S; Sadr A; Johnston L; Hull M; Montaner J; Moodie E; Pick N; Rachlis A; Rouleau D; Sandre R; Tyndall JM; Vachon ML; Sanche S; Skinner S; Wong D
    Clin Infect Dis; 2016 Jan; 62(2):242-249. PubMed ID: 26400998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of HAART on liver histology of HIV/HCV coinfected patients.
    De Bona A; Sitia G; Uberti-Foppa C; Galli L; Ciuffreda D; Gallotta G; Paties C; Lazzarin A
    J Biol Regul Homeost Agents; 2003; 17(2):195-7. PubMed ID: 14518723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.
    Raboud J; Anema A; Su D; Klein MB; Zakaryan A; Swan T; Palmer A; Hosein S; Loutfy MR; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Hogg RS; Cooper C;
    HIV Clin Trials; 2012; 13(2):90-102. PubMed ID: 22510356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
    Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Carrieri P; Neau D; Morlat P; Marchou B; Dabis F; Salmon D;
    HIV Med; 2013 Aug; 14(7):430-6. PubMed ID: 23461846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.